BioWorld

Critical Path Institute funds development of QED-203 for advanced prostate cancer

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
EurekAlert!

C-Path’s TRxA announces $1 million award for drug development project in type 1 diabetes

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
EurekAlert!

C-Path’s PKD outcomes consortium receives BAA Award for project to advance drug development tools for autosomal dominant tubulointerstitial kidney disease

TUCSON, Ariz., Sept. 19, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant ...
News Medical

Navigating the future of drug development at the C-Path Global Impact Conference

Critical Path Institute (C-Path), whose mission is to lead collaborations that accelerate drug development, advancing better treatments for people worldwide, is proud to announce its inaugural C-Path ...
News Medical

C-Path releases new publication on transforming drug development for neurological disorders

Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a ...